What Flavedon-MR Treats: Main Uses and Benefits

Flavedon-MR is commonly used in adults for the symptomatic treatment of stable angina pectoris, a chronic condition characterized by symptoms related to physical discomfort in the chest. Its role is relevant: it may be applied when supportive symptom management is needed in situations where patients are inadequately controlled by or intolerant to standard first-line therapies.

The primary focus plays a role in managing symptoms linked to myocardial ischemia and supporting function in conditions where episodic or fluctuating manifestations are present. This provides supportive relief when symptoms interfere with routine activities. The indications are relevant to persistent chest discomfort, pain associated with reduced blood flow, and associated limitations in physical capacity.

“The primary goal is to help maintain a sense of stability when symptoms are more noticeable, assisting with functional stability during periods of heightened discomfort.”

In these scenarios, Flavedon-MR assists with maintaining functional stability and generally contributes to greater day-to-day comfort.

Quick Fact: Supportive Symptomatic Relief for Anginal Chest Discomfort

Regulatory References

1. European Medicines Agency restriction recommendation

Eligibility Profile: Contraindications and Restrictions

Flavedon - MR (Trimetazidine Dihydrochloride) is indicated for use in adults only. Eligibility for this medicine is strictly defined by government regulatory documents, which include several absolute prohibitions and special caution requirements based on patient characteristics.

Absolute Non-Eligibility (Contraindicated)

The medicine must not be used in the following patient populations, as stated in the regulatory label:

• Patients with Parkinson disease or other related movement disorders, including parkinsonian symptoms, tremors, or restless leg syndrome.
• Patients with Severe renal impairment, defined as having a creatinine clearance rate less than 30 mL/min.
• Patients with known hypersensitivity to Trimetazidine Dihydrochloride or any excipients.

Restricted and Non-Established Use

Population Group	Regulatory Status
Pediatric Population (Below 18 years)	Not recommended; safety and efficacy have not been established.
Moderate Renal Impairment	Requires caution and special consideration; use is conditional on proper management.
Elderly Patients (Over 75 years)	Requires caution due to potential for increased drug exposure.
Pregnancy and Breastfeeding	Not recommended due to insufficient human safety data.

This framework ensures that the medicine is reserved for the officially designated eligible population and excluded from groups for whom use is formally prohibited.

The official regulatory profile for Trimetazidine Dihydrochloride (Flavedon-MR) documents a low potential for interaction with other medicines and products. Prescribing information consistently confirms that no specific drug-drug interactions have been identified or formally reported, and no metabolic or transporter-mediated interaction mechanisms are cited. Consequently, the official documents do not list any interaction-related prohibitions or mandatory dose-separation rules for co-administered agents. Furthermore, the drug's pharmacokinetic characteristics are not influenced by the presence of food, eliminating any documented drug-food timing constraints.

The sole constraint within the interaction context involves a formally documented population-dependent pharmacokinetic alteration linked to elimination:

Pharmacokinetic Constraint	Regulatory Statement
Altered Clearance	The clearance of Trimetazidine is reduced in specific patient groups.
Affected Populations	Elderly patients (over 75 years of age) and patients with moderate renal impairment (creatinine clearance 30-60 mL/ min).
Outcome	An official increase in systemic exposure (plasma concentration) is expected in these populations due to age-related and condition-specific decreases in renal function.

This interaction structure is defined by the absence of specific drug-drug and drug-food interaction patterns and the presence of a mandatory restriction tied to physiological function, as stated in official regulatory documentation.

Flavedon - MR (Trimetazidine) operates as a metabolic modulator, altering the substrate utilization for ATP generation in cardiac cells. Its action is focused on metabolic pathways, without direct or primary effects on systemic hemodynamics.

Inhibition of Fatty Acid Oxidation

The core mechanism is the selective inhibition of the mitochondrial enzyme long-chain 3-ketoacyl coenzyme A thiolase (3-KAT), a key enzyme in the fatty acid beta-oxidation pathway. By inhibiting this step, the drug shifts the cell's energy substrate preference toward glucose oxidation. This shift is established because glucose metabolism requires less oxygen to produce ATP compared to fatty acid metabolism.

Cellular Cytoprotection and Homeostasis

The modulated energy utilization leads to a sequence of intracellular events classified as cytoprotection. This sequence limits the buildup of H^+ ions, mitigating intracellular acidosis and the subsequent pathological activation of Na^+/ H^+ and Na^+/ Ca^2+ exchange pumps. This mechanism contributes to maintaining the structural and ionic equilibrium of the cardiac cell membrane and mitochondria under conditions of reduced oxygen availability.

Resulting Physiological Effect

The combination of metabolic modulation and ionic stabilization leads to an increased ratio of work performed to oxygen consumed, which is the definition of increased myocardial oxygen efficiency. This mechanistic profile is associated with preserved cellular function under periods of oxygen deficiency.

How to Use Flavedon - MR: Administration Guidelines

Flavedon - MR (Trimetazidine Dihydrochloride 35 mg Modified-Release Tablet) is administered according to specific procedural guidelines. These instructions ensure the active substance is released slowly and effectively over time.

Administration and Dosage

Category	Instruction
Route of Administration	Oral (taken by mouth).
Standard Adult Dose	One 35 mg tablet.
Dosing Frequency	Twice daily (BID), morning and evening.
Timing of Intake	Must be taken during meals.

Procedural Instructions and Adjustments

To preserve the modified-release mechanism, the tablet must be swallowed whole. It should not be crushed, broken, or chewed under any circumstances. If a dose is forgotten, the next dose should be taken at the usual time; doubling the next dose is not permitted.

Population-Specific Rules:

• Patients with Moderate Renal Impairment (Creatinine Clearance 30 to 60 ml/min): The dose is adjusted to one 35 mg tablet once daily in the morning.
• Older Adults: Caution is required, and the dose may be adjusted based on renal function.
• Children and Adolescents (le 18 years): Use is not recommended due to a lack of established safety and efficacy data.

Research evidence / Overview of studies for Flavedon - MR

---

Evidence Base for Stable Angina Pectoris (Add-on Therapy)

Research supporting the regulatory scope of Flavedon - MR was conducted in the context of stable angina pectoris, a condition characterized by fluctuating manifestations of chest discomfort due to restricted heart blood flow. The medication was mainly studied in research settings as a complementary therapy for adult patients whose symptoms persisted despite already receiving standard care, such as beta-blockers or calcium channel blockers.

The research primarily relied on short-term randomized controlled trials (RCTs). These trials included measurements examining patient-reported experiences and monitoring physiological strain or stress over defined time intervals. Subsequent meta-analyses aggregated data from these short-term studies to provide a broader summary of the research.

---

What Research Evaluated: Symptoms and Physical Function

The studies monitored outcomes related to physical discomfort and daily functioning. Key measurements included weekly tracking of the frequency of angina attacks and the amount of short-acting nitrate medication that patients needed to take. Studies also monitored physiological strain through controlled testing, where they explored the time it took for a patient to develop signs of restricted heart blood flow during physical exertion, as well as the patient's total exercise duration. Findings describe patterns observed in these functional outcomes, indicating measured changes during the study period.

---

Research Gaps and What Remains Unclear

One key limitation noted by regulatory reviewers is the reliance on surrogate endpoints; the most frequently reported measures tracked symptomatic and functional changes, rather than major long-term clinical outcomes (like mortality or heart attack rates). The core evidence is focused on short- to intermediate-term observation periods, typically up to six months. Consequently, the long-term effects are not fully established.

While studies include patients with comorbidities like high blood pressure or Type 2 diabetes mellitus, comparative research against established first-line angina drugs remains limited. The evidence remains limited regarding its role in long-term clinical events.

Common questions about Flavedon - MR (FAQ)

Q: What is the function of the MR in the drug name?

A: The abbreviation MR stands for Modified-Release. This formulation is designed to ensure the active substance is released slowly and consistently into the body over an extended period. This controlled release profile is consistent with the drug’s prescribed dosing regimen.

Q: What does the term 'metabolic agent' mean in relation to Flavedon - MR?

A: Flavedon - MR is classified as a metabolic agent because it alters the way heart cells use energy. Its mechanism shifts the cell's energy preference toward a more oxygen-efficient process called glucose oxidation. This action supports the heart muscle's function when oxygen supply is restricted.

Q: What is the role of Flavedon - MR in heart cell protection?

A: The role of the medicine is to protect heart cells during periods of low oxygen (ischemia). This cellular protection occurs by optimizing energy use, which helps maintain the structural and ionic balance within the cell and limits damage such as internal cell acidosis.

Q: Is Flavedon - MR a beta-blocker?

A: Flavedon - MR is classified as a metabolic anti-ischemic agent. Its primary function is to optimize heart cell energy use, and it does not operate as a beta-blocker. Official regulatory information indicates it does not have a direct or primary effect on blood pressure or heart rate.

Q: How does Flavedon - MR affect energy use in the body?

A: The metabolic effect is focused on optimizing energy use within the heart cells. Official regulatory documents indicate that the effect is localized to the heart cells and that the medicine does not have a direct or primary effect on overall systemic functions like general blood pressure or heart rate.

Q: Is Flavedon - MR a generic drug?

A: The active ingredient in Flavedon - MR is Trimetazidine Dihydrochloride. This substance is available under its generic name and in various other branded products worldwide.

Q: Are there different strengths of Flavedon - MR available?

A: The dose for Flavedon - MR modified-release tablets discussed in the official regulatory profile is the 35 mg strength.

Q: How quickly does Flavedon - MR start working?

A: According to official pharmacokinetic data, maximum concentration of the active substance in the blood is generally reached after approximately five hours after taking the modified-release tablet.

Q: What is the expected time frame to notice the effects of Flavedon - MR?

A: A stable concentration of the medicine in the blood is generally reached after approximately 60 hours of use. The benefit of the treatment is officially subject to assessment by a physician after three months.

Q: What does the research say about Flavedon - MR and exercise tolerance?

A: Clinical studies reviewed by regulatory bodies indicate that when Flavedon - MR is added to standard therapy, it can improve parameters related to physical exertion. This includes increased total exercise duration and the time until physical discomfort occurs during testing.

Q: Can Flavedon - MR be used for heart pain?

A: Flavedon - MR is officially indicated as an add-on therapy for the symptomatic treatment of stable angina pectoris. This is a specific condition characterized by chest discomfort caused by restricted blood flow to the heart.

Q: Why would a doctor prescribe Flavedon - MR instead of something else?

A: Official marketing authorization specifies that this medicine is used as an add-on therapy for patients with stable angina pectoris. It is generally reserved for those whose symptoms are not adequately controlled by, or who are intolerant to, other first-line anti-anginal therapies.

Q: What is the difference between Flavedon - MR and other medicines for similar conditions?

A: Flavedon - MR is classified as a metabolic agent that works by changing how the heart muscle uses energy, distinguishing it from agents that focus primarily on blood pressure or heart rate.

Q: Is Flavedon - MR known to cause dizziness?

A: Dizziness is listed in official regulatory documents as a common side effect.

Q: Are there any common digestive side effects with Flavedon - MR?

A: Official labeling documents common digestive side effects, which include nausea, vomiting, abdominal pain, diarrhea, and indigestion (dyspepsia).

Q: What is the half-life of Flavedon - MR?

A: The average elimination half-life is typically 7 hours. Official prescribing information indicates that this period can increase to approximately 12 hours in older patients (over 65 years).

Q: Are there regulatory warnings about Flavedon - MR?

A: Yes, the official labeling contains specific warnings and contraindications. These include the risk of developing or worsening Parkinsonian symptoms, and prohibitions for use in patients with existing movement disorders or severe renal impairment.

Q: Is the effect of Flavedon - MR reversible after stopping the treatment?

A: The movement disorders, such as Parkinsonian symptoms, which can be caused by the medicine, are generally reversible. Symptoms typically resolve within four months after treatment is discontinued.

Q: Why do some people say they take Flavedon - MR for vertigo?

A: The use of this medicine for conditions like vertigo or other balance issues has been deleted from its official marketing authorization. Regulatory bodies concluded that the benefits for these conditions were not sufficiently demonstrated. The official indication is restricted to stable angina pectoris.

Q: Is Flavedon - MR prescribed for tinnitus?

A: The use of this medicine for tinnitus (ringing in the ears) is not officially authorized. Regulatory bodies concluded that the benefits for this condition were not sufficiently demonstrated, and the official indication is restricted to stable angina pectoris.

Q: Can Flavedon - MR be crushed or chewed?

A: No. The Modified-Release tablet must be swallowed whole. Official instructions forbid crushing, breaking, or chewing the tablet because this would destroy the mechanism that controls the slow release of the active substance over time.

Q: What happens if I forget to take a dose of Flavedon - MR?

A: If a dose is forgotten, the next dose is taken at the usual time. Official guidelines prohibit taking a double dose to make up for the missed amount.

Q: Is it okay to drink alcohol while taking Flavedon - MR?

A: Official prescribing information does not list a specific interaction with alcohol. Since the medicine can cause dizziness, patients are encouraged to discuss alcohol consumption with their prescribing physician.

Q: Can Flavedon - MR interact with herbal supplements?

A: While official information states no specific drug-drug interactions have been identified or formally reported, patients typically discuss all co-administered supplements with their physician.

Q: Is it necessary to have regular check-ups while on Flavedon - MR?

A: Regulatory guidance advises that the treatment benefit should be assessed by a physician after three months of use. Regulatory guidance advises monitoring patients for any new or worsening movement disorders, such as tremor or difficulty walking.

Q: What if I experience unusual muscle stiffness while taking Flavedon - MR?

A: Official regulatory guidance directs that if movement disorders like muscle stiffness, tremor, or difficulty walking occur, the medicine is typically discontinued and a physician is consulted. If symptoms persist for several months after stopping the drug, a specialist opinion may be sought.

Q: What is the guidance on using Flavedon - MR during pregnancy?

A: Official documents state that use during pregnancy is not authorized as a precautionary measure due to a lack of sufficient human data.

Q: Is there information about Flavedon - MR use during breastfeeding?

A: Official documents state that use during breastfeeding is not authorized due to a lack of data on whether the medicine passes into breast milk.

Q: What happens if I stop taking Flavedon - MR suddenly?

A: Official guidelines specify that the treatment is typically discontinued by a physician if the expected response is not achieved after three months. No specific effects of sudden cessation are noted in prescribing information.

How to Store and Dispose of Flavedon MR

Storage of Flavedon MR (Trimetazidine Dihydrochloride modified-release tablets) must comply strictly with labeled regulatory conditions to maintain product stability and safety.

Official Storage Conditions

The tablets must be stored at a temperature not exceeding 30 C in a cool and dry place. Protection from direct sunlight and moisture is required. The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Flavedon MR must be performed in accordance with local requirements for pharmaceutical waste. General guidance for non-controlled medicines suggests using a drug take-back program if available. If no take-back program exists, the product should typically be mixed with an undesirable substance (such as dirt) and sealed before disposal in the household trash, following the guidance of the national regulatory authority.